Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks ...
BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ...
Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported positive results from the CINGAL ® 13 ...
Anika Therapeutics Inc (NASDAQ: ANIK) announced that Cingal met its primary endpoint in a Phase 3 Study (Cingal 19-01), demonstrating superiority over triamcinolone hexacetonide (TH) steroid alone at ...
Anika Therapeutics (ANIK-2.8%) completes the enrollment of 242 patients in its Phase 3 Cingal 13-02 study, an open-label follow-on to Cingal 13-01, to evaluate repeat injections of Cingal (Hyaluronic ...
If you're looking for biotech stock bargains, the scrap heap isn't a bad place to start. Hardly a day goes by without a biotech meltdown somewhere, and clinical trial mishaps led to market clubbings ...
Shares of Anika Therapeutics Inc (NASDAQ:ANIK) slumped 37% after the company reported disappointing data from its phase III Cingal 16-02 study. The 16-02 trial compared Cingal, a combination of ...
BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary ...
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback